Compare · DFTX vs MDWD
DFTX vs MDWD
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and MediWound Ltd. (MDWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MDWD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.98B, about 27.3x MDWD ($182.2M).
- Over the past year, DFTX is up 432.2% and MDWD is down 29.9% - DFTX leads by 462.2 points.
- DFTX has hit the wire 27 times in the past 4 weeks while MDWD has been quiet.
- MDWD has more recent analyst coverage (8 ratings vs 5 for DFTX).
- Company
- Definium Therapeutics Inc.
- MediWound Ltd.
- Price
- $45.66-0.64%
- $14.15-1.50%
- Market cap
- $4.98B
- $182.2M
- 1M return
- +84.54%
- -0.67%
- 1Y return
- +432.23%
- -29.93%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 27
- 0
- Recent ratings
- 5
- 8
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest DFTX
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,315,236 worth of shares (29,208 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,098,246 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Wiley Matthew T. sold $129,101 worth of shares (2,867 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,633 units (SEC Form 4) (withholding obligation)
- A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
- Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Latest MDWD
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)
- Director Rubinstein Samuel bought $2,150 worth of Ordinary Shares (150 units at $14.33), increasing direct ownership by 5% to 2,993 units (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by MediWound Ltd.
- MediWound to Report First Quarter 2026 Financial Results
- SEC Form 6-K filed by MediWound Ltd.
- Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences